<qa>  What is the name of the drug that is more likely to respond to?Current clinical trials are showing that patients whose tumors are mismatch repair deficient are more likely to respond to immune-boosting anti-PD-1 drugssuch as pembrolizumabthan those with tumors proficient in mismatch repair. The idea is that the greater the number of DNA glitches in a tumor cell, the more abnormal proteins it will produceand the more abnormal proteins that are generated, the greater the odds that the bodys immune cells will regard the tumor cells as foreign and target them for destruction. Thus far, PD-1 inhibitors have shown great promise for mismatch repair deficient cancer patients, but not for mismatch repair proficient MRP cancer patients. 